MONTREAL, Dec. 21,
2023 /PRNewswire/ - Theratechnologies Inc.
("Theratechnologies" or the "Company") (Nasdaq: THTX) (TSX:
TH), a biopharmaceutical company focused on the development and
commercialization of innovative therapies, today announced that it
has filed a preliminary short form base shelf prospectus with the
securities regulatory authorities of all the provinces of
Canada and a corresponding shelf
registration statement with the United States Securities and
Exchange Commission (the "SEC") on Form F-3.
The filing is made for the purpose of restoring the original
financing capacity which was available to Theratechnologies under
its previous base shelf prospectus dated
December 14, 2021 expiring on January 14, 2024.
Once the Canadian securities regulatory authorities have issued
a receipt for the final short form base shelf prospectus and the
shelf registration statement becomes effective, these filings will,
subject to securities regulatory requirements, provide for the
potential offering in Canada and the United
States of up to an aggregate of US$100,000,000 of common shares, preferred
shares, subscription receipts, warrants, debt securities and units
from time to time over a 25-month period. These filings are
intended to give the Company the flexibility to take advantage of
financing opportunities when market conditions are favourable. The
terms of such future offerings, if any, will be established at the
time of such offerings. At the time any of the securities covered
by these filings are offered for sale, a prospectus supplement
containing specific information about the terms of any such
offering will be filed with applicable Canadian securities
regulatory authorities and the SEC.
The shelf registration statement filed with the SEC has not
yet become effective. No securities may be sold, nor may offers to
buy be accepted, prior to the time the registration statement
becomes effective. This press release shall not constitute an
offer to sell or a solicitation of an offer to buy, nor shall there
be any offer, solicitation or sale of, securities in any province,
state or jurisdiction in which such offer, solicitation or sale
would be unlawful prior to registration or qualification under the
securities laws of any such jurisdiction.
A copy of the preliminary base shelf prospectus will be
available on our SEDAR+ profile at www.sedarplus.ca and a copy of
the corresponding shelf registration statement is available on
EDGAR at www.sec.gov. Alternatively, a copy of such documents is
available upon request by contacting the Company's Corporate
Secretary at 2015 Peel Street, Suite 1100, Montreal, Quebec, Canada, H3A 1T8, telephone:
(514) 336-7800.
About Theratechnologies
Theratechnologies (Nasdaq: THTX) (TSX: TH) is a
biopharmaceutical company focused on the development and
commercialization of innovative therapies addressing unmet medical
needs. Further information about Theratechnologies is
available on the Company's website at www.theratech.com, on
SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov.
Forward-Looking
Information
This press release contains forward-looking statements, within
the meaning of Section 21E of the Securities Exchange Act
of 1934, as amended and forward-looking information under
applicable Canadian securities laws (such forward-looking
statements and forward-looking information are collectively
referred to herein as "forward-looking statements"), that are based
on our management's beliefs and assumptions and on information
currently available to our management. You can identify
forward-looking statements by terms such as "may", "will",
"should", "could", "would", "outlook", "believe", "plan",
"envisage", "anticipate", "expect" and "estimate", or the negatives
of these terms, or variations of them. The forward-looking
statements contained in this press release include, but are not
limited to, statements regarding the offer and sale of
securities.
We refer potential investors to the "Risk Factors" section of
our annual information form dated February
27, 2023 available on SEDAR+ at www.sedarplus.ca and on
EDGAR at www.sec.gov as an exhibit to our report on
Form 40-F dated February 28,
2023 under Theratechnologies' public filings for additional
risks regarding the conduct of our business and Theratechnologies.
The reader is cautioned to consider these and other risks and
uncertainties carefully and not to put undue reliance on
forward-looking statements. Forward-looking statements reflect
current expectations regarding future events and speak only as of
the date of this press release and represent our expectations as of
that date.
We undertake no obligation to update or revise the information
contained in this press release, whether as a result of new
information, future events or circumstances or otherwise, except as
may be required by applicable law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/theratechnologies-announces-renewal-of-shelf-prospectus-and-filing-of-registration-statement-302021334.html
SOURCE Theratechnologies Inc.